We at Esteve Química are committed to the Health Care Industry by supporting the development and commercialization of products that contribute to the better wellbeing of people.
Our company was founded in 1966 within one of the largest Pharmaceutical Groups in Spain (Esteve). Ever since the beginning, we were able to implement an API manufacturing concept that gathers the best of the chemical and pharmaceutical worlds by using state-of-the-art technologies and installations, such as clean room areas for the last steps of manufacturing.
Esteve Química has 50 years of experience developing, manufacturing and marketing oral and injectable-non-sterile APIs (NCEs and generics) for regulated markets. In addition to our generics business, we currently offer our API’s with a Finished Dosage File by establishing alliances with strategic pharmaceutical manufacturers and partners.
Please find out more about how we can support you.
We are currently active in two business areas: contract manufacturing for third parties (APIs and pharmaceutical intermediates) and generics (not only from the API perspective, but also for FDFs with strategic partners), always focusing on long-term partnerships.
Our products are used in a wide range of applications, from solid oral dosage forms to injectable forms.
We have been exporting APIs to the most highly regulated markets for the last 50 years and we are inspected regularly by the major Health Authorities.
Our development capabilities, deep knowledge, fast adaptation to customers’ requirements and regulations, technical capabilities, strategic geographical location and, particularly, commitment to excellence, allow ensuring optimum service and reliable response whatever the scale of the project.
Industrial Spray Drying and HPAPI in Spain
First FDA inspection in Sintenovo, Jiutepec (Mexico)
AEMPS (Spanish Authorities) Inspection for pre-formulated products in Celrà, Spain
Transfer of commercial products from Naucalpan to Jiutepec.
Closing of Naucalpan API plant in Mexico
First generic formulated product (API from Esteve Química) results from strategic alliance: montelukast
First FDA Inspection in EHP, China (Shaoxing)
Our second joint-venture in China (EHP) starts activities with Shaoxing plant
Acquisition of an API plant in Spain (Banyeres)
Acquisition of second API plant in Mexico (Jiutepec)
First joint venture in China (ZHP)
Acquisition of the first API plant in Mexico (Naucalpan). Initiation of Internationalization
New API plant in Spain (Celrà)
FDA first inspection in Spain (Barcelona)
Esteve Química starts up activities in Barcelona